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Background: We aimed to establish a Medical-Insurance-System-based Cancer Surveillance System (MIS-
CASS) in China and evaluate the completeness and timeliness of this system through reporting cancer inci-
dence rates using claims data in two regions in northern and southern China.
Methods: We extracted claims data from medical insurance systems in Hua County of Henan Province, and
Shantou City in Guangdong Province in China from Jan 1, 2012 to Jun 30, 2019. These two regions have been
considered to be high risk regions for oesophageal cancer. We developed a rigorous procedure to establish
the MIS-CASS, which includes data extraction, cleaning, processing, case ascertainment, privacy protection,
etc. Text-based diagnosis in conjunction with ICD-10 codes were used to determine cancer diagnosis.
Findings: In 2018, the overall age-standardised (Segi population) incidence rates (ASR World) of cancer in
Hua County and Shantou City were 167¢39/100,000 and 159¢78/100,000 respectively. In both of these areas,
lung cancer and breast cancer were the most common cancers in males and females respectively. Hua County
is a high-risk region for oesophageal cancer (ASR World: 25¢95/100,000), whereas Shantou City is not a high-
risk region for oesophageal cancer (ASR World: 11¢43/100,000). However, Nanao island had the highest inci-
dence of oesophageal cancer among all districts and counties in Shantou (ASR World: 36¢39/100,000). The
age-standardised male-to-female ratio for oesophageal cancer was lower in Hua County than in Shantou
(1¢69 vs. 4¢02). A six-month lag time was needed to report these cancer incidences for the MIS-CASS.
Interpretation: MIS-CASS efficiently reflects cancer burden in real-time, and has the potential to provide
insight for improvement of cancer surveillance in China.
Funding: The National Key R&D Program of China (2016YFC0901404), the Digestive Medical Coordinated
Development Center of Beijing Municipal Administration of Hospitals (XXZ0204), the Sanming Project of
Shenzhen (SZSM201612061), and the Shantou Science and Technology Bureau (190829105556145,
180918114960704).
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Research in context
Evidence before this study
Surveillance-site-based cancer registration has been the only
approach for estimating the national incidence of cancer in China.
However due to the vast territory, huge population, and limited
resources of China, it is almost impossible to establish a nationwide
population-level cancer surveillance system with a short time lag
using this traditional method. Claims data in health insurance sys-
tems have been used to identify incident cancer cases in western
countries (We searched PubMed, Google Scholar, and China
National Knowledge Infrastructure for studies published before Sep
1, 2019, with no language restriction, using the terms “cancer inci-
dence”, “health insurance system”, “claims data”, etc.). Moreover,
we have already conducted two comparative studies which dem-
onstrate the feasibility and accuracy of identifying cancer cases
using claims data extracted from health insurance systems in rural
China. However, whether the Medical-Insurance-System-based
Cancer Surveillance System (MIS-CASS) can be applied to urban as
well as rural areas on a large scale in China has as yet not been
determined.
Added value of this study
We, for the first time, established a MIS-CASS and evaluated its per-
formance in both urban and rural China in this study. We demon-
strated that claims data from medical insurance systems have great
potential for application in identifying newly diagnosed cancer
cases, and showed that the MIS-CASS is feasible, representative,
accurate, timely and inexpensive for monitoring the current status
and trends of all-site cancer incidence in China.
Implications of all the available evidence
We recommend adoption and further evaluation of the MIS-CASS
on a larger scale, which will provide new insight into the reform
and development of national level cancer surveillance in China.
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Cancer is the second most frequent cause of death among non-
communicable diseases. In 2018, there were 18¢1 million new cancer
cases worldwide and 9¢6 million persons died of cancer [1]. In China,
there were 4¢3 million new cancer cases in 2018, and 6¢7 million
cases are projected to occur in 2040 [2]. Continuous and accurate sur-
veillance of cancer incidence is crucial for determination of actual
cancer burden, and for efficient allocation of medical resources, as
well as for timely launching of preventive strategies.
Cancer registration is defined as “the process of continuing, system-
atic collection of data on the occurrence and characteristics of report-
able neoplasms” [3]. Population-based cancer registration (PBCR) is
acknowledged to be the gold standard method for reporting cancer
incidence in a defined population [4]. Currently, national-level cancer
registration has been established in some developed countries such as
Austria, Belgium, Canada, Finland, Ireland, and South Korea [5]. In
China however, it is unrealistic to establish real nation-wide PBCR due
to the vast territory of China and its huge population and limited
resources. Sentinel surveillance, that is, establishing surveillance sites
in certain areas to estimate national level cancer incidence, has to date
been the only approach used in China. As many as 449 cancer surveil-
lance sites had been established in China up to 2014. However, only 36
of these surveillance sites which were mostly in areas of high-risk for
specific cancers or economically developed regions were of highquality and were included in the latest volume of Cancer Incidence in
Five Continents, accounting for 5% of the national Chinese population
[68]. Moreover, there has been a characteristic three-year lag in
reporting cancer statistics in China due to the time and resource con-
suming process of data collection, quality control, and data analysis
[9]. For example, the latest annual cancer report (published in Jan
2019) was based on data for the year of 2015 [10].
Claims data in health insurance systems have been applied to
identify incident cancer cases in some western countries, and the
performance of this method has been previously validated [11,12]. In
China, basic medical insurance systems are completely administered
and operated by the central and local governments. Urban Employee
Basic Medical Insurance (UEBMI, initiated in 1998), the New Rural
Co-operative Medical Care Scheme (NCMS, initiated in 2003), and
Urban Residents Basic Medical Insurance (URBMI, initiated in 2007)
constitute China’s basic medical insurance systems, and cover over
95% of the national population [13]. In 2018, the establishment of the
National Healthcare Security Administration directly under the State
Council brought about integration of China’s basic medical insurance
systems, which has facilitated the standardised management of med-
ical claims data in China [14].
Accuracy (validity), completeness, comparability and timeliness
are the crucial principles for cancer surveillance [15,16]. The quality
of claims data per se determines the accuracy and completeness of
collecting cancer cases, and two of our preceding studies have
addressed this issue. In one study we compared active follow-up
(door-to-door interviews) with passive linkage with NCMS claims
data for identification of incident cancer cases in a large-scale ran-
domized controlled trial involving 33,948 subjects from 2012 to
2017, and found that the overall sensitivity of passive linkage with
NCMS claims data was significantly higher than that of active follow-
up (95¢6% vs 54¢9%, p < 0¢001) [17]. In another study, we further veri-
fied claims-based diagnoses with corresponding electronic medical
records at an individual level in the general population in Hua County
in 2017. We found that use of claims data identified cancer patients
with high sensitivity (92¢095¢2%) and positive predictive value
(89¢097¢8%) [18]. Both of these two comparative studies demon-
strated that claims data extracted from health insurance systems is
an ideal and accurate data source for identification of cancer cases. At
the same time, claims data are generated and submitted to corre-
sponding medical insurance systems in real time, which notably low-
ers the cost and the time lag involved in data collection and quality
control [19]. Based on these findings, we assumed that establishing a
population-level cancer surveillance system based on medical insur-
ance system claims data in China would be feasible, representative,
accurate, timely, and inexpensive.
Hua County (Taihang Mountain area) in Henan Province and
Shantou City (Chaoshan area) in Guangdong Province are known as
areas of high oesophageal cancer incidence (Supplementary Figure 1)
[20,21]. However, no cancer registries have been established in either
of these two regions, leaving uncertainty about the actual patterns of
cancer incidence and oesophageal cancer burden there.
In this study, we established a Medical-Insurance-System-based
Cancer Surveillance System (MIS-CASS) and evaluated the complete-
ness and timeliness of the MIS-CASS by reporting all-site cancer inci-
dence in 2018 together with temporal trends of common cancer
incidence from 2014 to 2018 in Hua County and Shantou City.
Method
Medical insurance systems in Hua County and Shantou City
Hua County is located in northern Henan Province and covers an
area of 700 square miles (Supplementary Figure 1). This area is pre-
dominantly rural and 90% of the total population is involved in agri-
culture. In 2018, Hua County was home to 1¢07 million permanent
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Yuan (US $3715) [2224]. The sole medical insurance system in rural
Hua County is the NCMS, which is a government-run, voluntary, com-
munity-based, cost-sharing medical insurance programme. This pro-
gramme has covered 99% of the local rural residents since 2010 [25].
Shantou City is located in eastern Guangdong Province and covers
797 square miles (Supplementary Figure 1). It consists of six districts
(Chaonan, Chaoyang, Jinping, Longhu, Haojiang, and Chenghai) and
one county (Nanao). In 2018, Shantou City was home to 5¢62 million
permanent residents, with a per capita GDP of 44,672 Yuan (US
$6751) [22,26]. The medical insurance systems in Shantou include
UEBMI, URBMI, and NCMS, and the overall rate of enrollment has
exceeded 90% in recent years.
Source of claims data
We extracted the medical claims data from Jan 1, 2012 to Jun 30,
2019 from the NCMS system in Hua County and the UEBMI, URBMI,
and NCMS systems in Shantou City. The key variables included but
were not limited to gender, year of birth, admission date, name of the
hospital where the diagnosis was established, text-based diagnosis,
International Classification of Diseases (tenth revision, ICD-10) code,
and reimbursement date. All of the hospitals of record were classified
as “grade 300, “grade 200, or “grade 1 or unrated” in descending order
of their qualification for cancer diagnosis, according to the official
database of the National Health Commission of the People's Republic
of China (zgcx.nhc.gov.cn:9090/unit/index).
Data security and confidentiality
Data security and confidentiality are crucial preconditions for the
use of big data in healthcare. We established rigorous procedures in
this study to guarantee security of the data over the course of data
extraction, storage, processing, and statistical analysis. To secure pro-
tection of privacy, we masked individual-level identifiable personal
information including name, identity (ID) number, medical insurance
card number, telephone number, and home address. We then gener-
ated a unique, encrypted hexadecimal identification code for each
patient as a label to further ensure elimination of duplicate diagnostic
records.
Identification of incident cancer cases
A window of at least two years was set to exclude prevalent can-
cer cases by washing out repeated diagnoses emerging in the follow-
ing years, as the cancer incidence rates in 2018 remained stable
when the time window was reset from two years (20162017) to six
years (20122017) (Supplementary Figure 2). We also used the
records from the first six months of 2019 to avoid missing claims
records due to reimbursement delay, based on the fact that the pro-
portion of reimbursement delay over six months has been extremely
low (<2¢5%) in this study (Supplementary Figure 3).
We defined an incident cancer case on the basis of the first defi-
nite cancer-related claims record in each given case, with the corre-
sponding date of admission as the incidence date, according to the
recommendation of the European Network of Cancer Registries [15].
Text-based diagnosis and ICD-10 codes were used to ascertain cancer
diagnoses.
The procedure for identifying incident cancer cases in Hua County
and Shantou City is shown in Fig. 1. After data masking, the claims
records which represented cancer-related diagnoses were exported
from the medical insurance systems in these two regions once they
met any of the following criteria: a. ICD-10 codes ranged from C00 to
C97; b. Text-based diagnoses contained cancer-related key words,
including “cancer”, “carcinoma”, “sarcoma”, “malignant tumour”,
“leukaemia”, “lymphoma”, “Franklin disease”, “Alpha heavy chaindisease”, etc. (We reviewed the Chinese version of the ICD-10 and
constructed a dictionary which included all the key words indicating
a cancer diagnosis). Of all these extracted records, those diagnosed in
grade 1 or unrated hospitals (eg, township-level health centres) were
excluded due to insufficient diagnostic qualification, which is consis-
tent with the standard procedure of the National Central Cancer Reg-
istry of China. Cancer diagnoses were then determined using both
ICD-10 codes and text-based diagnoses. In cases of records where
any of the ICD-10 code or text-based diagnosis was missing, or the
cancer site determined by ICD-10 code disagreed with that deter-
mined by text-based diagnosis, active manual evaluation was per-
formed with group discussion among at least three trained
investigators with a background in oncology and epidemiology. Of all
the qualified claims records, ~3.5% needed to be confirmed manually,
and in only ~0.3% did disagreement arise among the investigators,
which were resolved by following the majority rule in group discus-
sion. For all claims records of each patient, only the first definite can-
cer diagnosis at a specific site during the study period was retained.
Data from the years 2012 and 2013 were removed in consideration
of prevalent cases, and data within the period Jan 1, 2014 to Dec 31,
2018 were defined as incident cancer diagnoses in this study. Multi-
ple primary cancer cases were determined after excluding extension,
recurrence or metastasis, which conforms to the international rules
for multiple primary cancers [27].
Statistical analysis
For cancers from all sites, crude incidence rates (CIR), age-specific
incidence rates, and age-standardised incidence rates (ASR) were cal-
culated by gender in Hua County and Shantou City in 2018 using the
corresponding insured population (the list of insured individuals was
updated annually) as the denominator (Fig. 2, Supplementary Figure
4). Calculation of ASRs was based on the China standard population
in 2000 (ASR China) and the Segi standard population (ASR World).
Stata (version 15.0) was used for data cleaning, cancer case extrac-
tion, and calculation of incidence rates.
(1) Crude incidence rate per 100,000=
New cancer cases in a given year
Insured population in the same year 100; 000
(2) Age-specific incidence rate per 100,000=
New cancer cases in a given age group
Insured population in the same age group100; 000
(3) Age-standardised incidence rate per 100,000=
P
Agespecific rate  Standard population in corresponding age groupP
Standard population
100; 000
Ethics committee approval
This study was approved by the Institutional Review Board of the
Peking University School of Oncology, China.
Result
Cancer patterns
In 2018, the age-standardised (Segi population) incidence rates
for cancer in Hua County and Shantou City were 167¢39/100,000
(164¢79/100,000 in males, 176¢72/100,000 in females) and 159¢78/
100,000 (179¢87/100,000 in males, 142¢05/100,000 in females)
respectively. In Hua County, the most commonly diagnosed cancer in
males was lung cancer, followed by oesophageal cancer, stomach
cancer, liver cancer, and colorectal cancer. The most commonly diag-
nosed cancer in females was breast cancer, followed by lung cancer,
cervical cancer, oesophageal cancer, and thyroid cancer. In Shantou
Fig. 1. The procedure for capturing new cancer cases frommedical insurance systems in Hua County, Henan Province and Shantou City, Guangdong Province.
aRecords were identified as cancer-related and exported if they met any of the following criteria: a. ICD-10 codes ranged from C00 to C97; b. text-based diagnoses contained
cancer-related key words such as “cancer”, “carcinoma”, “sarcoma”, “malignant tumour”, “leukaemia”, “lymphoma”, “Franklin disease”, “Alpha heavy chain disease”, etc.
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ectum, oesophagus, liver, and stomach; and breast, colorectum, lung,
cervix, and thyroid, in females (Table 1). In both Hua County and
Shantou City, the age distribution of incidence rates for common can-
cers could in general be characterized as “left skewed distribution”
which peaks in the elderly (such as oesophageal cancer, lung cancer,
stomach cancer, and colorectal cancer), and “symmetric peak distri-
bution”which peaks in middle age (such as breast cancer and cervical
cancer) (Supplementary Figure 5, 6).
In Hua County, incidence rates from 2014 to 2018 decreased for
oesophageal cancer in men, and increased for cancer from all sites in
men, and for breast cancer, cervical cancer, thyroid cancer, and can-
cer from all sites in women (Supplementary Figure 7). In particular,
we observed a sharp increase in the incidence of female breast cancer
from 2015 to 2016 (Supplementary Figure 7). In Shantou City, a trend
of increase in incidence rates was seen for lung cancer, colorectalcancer, and liver cancer in men as well as colorectal cancer in women,
whereas a decreasing trend was observed for oesophageal cancer and
stomach cancer in men (Supplementary Figure 8).
Oesophageal cancer
In Hua County, the incidence of oesophageal cancer ranked first in
20142015 and third in 20162018 in both sexes combined (Supple-
mentary Table 1a). The ASR world for oesophageal cancer in 2018
was 25¢95/100,000 (34¢78/100,000 in males, ranked second; 18¢72/
100,000 in females, ranked fourth) (Table 1a). By contrast, in Shantou
City oesophageal cancer ranked fifth throughout the study period in
both sexes combined except 2017 (when it ranked fourth), and the
ASR world for oesophageal cancer was 11¢43/100,000 (18¢50/100,000
in males, ranked third; 4¢79/100,000 in females, ranked eighth) in
2018 (Table 1b, Supplementary Table 1a).
Fig. 2. Population pyramid of the insured population in Hua County, Henan Province and Shantou City, Guangdong Province, China, 2014 and 2018.
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44% of that in Hua County. However, distinct disparity in geographi-
cal pattern in the incidence of oesophageal cancer within Shantou
City was observed. In 2018, Nanao, which is a part of Shantou City,
was home to only 1¢4% of the population in Shantou City, but had the
highest incidence of oesophageal cancer (ASR World 36¢39/100,000).
This was more than twice as high as that in adjacent Chenghai, and
six times as high as that in Chaonan, which is the district most distant
from Nanao, and was even higher than that in Hua County (Fig. 3,
Supplementary Table 2).
We further compared the age and gender distribution of the inci-
dence of oesophageal cancer in Hua County and Shantou City. The inci-
dence rate was relatively low in individuals of less than 50 years, and
increased in ages over 50 in both of these two regions. However, differ-
ences in gender-specific risk of incident oesophageal cancer were
observed in these two regions. In Hua County, the male-to-female ASRWorld ratio for oesophageal cancer was only 1¢69, which was much
lower than that in Shantou City (ASRWorld ratio 4¢02) (Fig. 4).
Discussion
Over the past 20 years, sentinel-based cancer surveillance has
made a tremendous contribution in depicting the cancer burden in
China, and has provided a crucial basis for subsequent cancer-related
research and public health strategies. It has been an optimal strategy
for maintaining a cancer registration system taking into consider-
ation huge population and resource availability in China. However,
based on full population coverage by basic medical insurance systems
and the national-level integration of these systems in China, coupled
with the advent of the big-data era, it is time to reconsider cancer
surveillance strategies in China. In this study, we established a stan-
dard operation procedure for MIS-CASS, which includes privacy
Table 1a
Cancer incidence in Hua County, Henan Province, China, 2018.
Site ICD-10 Male and Female Male Female
Cases Proportion
(%)
CIR (1/105) ASR China
(1/105)
ASRWorld
(1/105)
Cases CIR (1/105) ASR China
(1/105)
A World
( 05)
Cases CIR
(1/105)
ASR China
(1/105)
ASRWorld
(1/105)
Lip, oral cavity, & pharynxa C00-C10, C12-C14 26 0¢93 2¢05 1¢52 1¢52 12 1¢83 1¢49 1 14 2¢29 1¢55 1¢47
Nasopharynx C11 7 0¢25 0¢55 0¢49 0¢42 4 0¢61 0¢46 0 3 0¢49 0¢54 0¢38
Oesophagus C15 474 17¢04 37¢43 25¢58 25¢95 277 42¢28 32¢01 3 8 197 32¢24 19¢92 18¢72
Stomach C16 218 7¢84 17¢22 12¢45 12¢34 167 25¢49 19¢25 2 4 51 8¢35 6¢32 5¢89
Colorectum C18-C21 181 6¢51 14¢29 10¢39 10¢14 86 13¢13 10¢76 1 7 95 15¢55 10¢01 9¢47
Liver C22 160 5¢75 12¢64 9¢37 9¢51 109 16¢64 13¢11 1 4 51 8¢35 5¢93 5¢72
Gallbladder C23-C24 55 1¢98 4¢34 2¢93 2¢80 28 4¢27 3¢14 3 27 4¢42 2¢75 2¢56
Pancreas C25 56 2¢01 4¢42 3¢16 3¢17 30 4¢58 3¢63 3 26 4¢26 2¢74 2¢61
Larynx C32 17 0¢61 1¢34 0¢94 0¢91 16 2¢44 1¢86 1 1 0¢16 0¢09 0¢09
Lung C33-C34 500 17¢98 39¢49 28¢51 28¢58 307 46¢86 36¢14 3 9 193 31¢59 21¢68 20¢57
Other thoracic organs C37-C38 9 0¢32 0¢71 0¢52 0¢52 4 0¢61 0¢51 0 5 0¢82 0¢52 0¢49
Bone C40-C41 17 0¢61 1¢34 1¢24 1¢25 9 1¢37 1¢39 1 8 1¢31 1¢09 1¢03
Melanoma of the skin C43 11 0¢40 0¢87 0¢76 0¢77 4 0¢61 0¢61 0 7 1¢15 0¢91 0¢93
Breast C50 296 10¢64 23¢38 22¢44 20¢05 1 0¢15 0¢10 0 295 48¢28 45¢35 40¢09
Cervix C53 148 5¢32 11¢69 10¢53 9¢64 NA NA NA N 148 24¢22 21¢01 18¢99
Uterus C54-C55 63 2¢27 4¢98 4¢30 4¢26 NA NA NA N 63 10¢31 8¢47 8¢40
Ovary C56 60 2¢16 4¢74 4¢23 3¢91 NA NA NA N 60 9¢82 8¢55 7¢81
Prostate C61 30 1¢08 2¢37 1¢64 1¢58 30 4¢58 3¢42 3 NA NA NA NA
Testis C62 4 0¢14 0¢32 0¢34 0¢32 4 0¢61 0¢65 0 NA NA NA NA
Kidney C64-C66, C68 35 1¢26 2¢76 2¢18 2¢13 27 4¢12 3¢26 3 8 1¢31 1¢12 1¢13
Bladder C67 24 0¢86 1¢90 1¢41 1¢40 17 2¢59 2¢07 2 7 1¢15 0¢85 0¢77
Brain, CNS C70-C72 21 0¢76 1¢66 1¢44 1¢41 7 1¢07 1¢14 1 14 2¢29 1¢73 1¢63
Thyroid C73 143 5¢14 11¢29 10¢11 9¢41 26 3¢97 4¢02 3 117 19¢15 16¢23 15¢04
Lymphoma C81-C85, C88, C90, C96 82 2¢95 6¢48 5¢18 5¢34 52 7¢94 6¢53 6 30 4¢91 3¢88 3¢83
Leukaemia C91-C95 67 2¢41 5¢29 4¢90 5¢01 37 5¢65 5¢42 5 30 4¢91 4¢34 4¢12
All other sites A_O 77 2¢77 6¢08 4¢70 5¢08 30 4¢58 4¢19 5 47 7¢69 5¢24 4¢97
All sites ALL 2781 100¢00 219¢63 171¢25 167¢39 1284 195¢98 155¢14 1 ¢79 1497 244¢99 190¢83 176¢72
a Nasopharyngeal cancer is excluded. ICD-10=International Classification of Diseases, tenth revision. CIR=crude incidence rate. ASR=age-standardised incidence rate. NA ot applicable.
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Table 1b
Cancer incidence in Shantou City, Guangdong Province, China, 2018.
Site ICD-10 Male and Female Male Female
Cases Proportion (%) CIR (1/105) ASR China
(1/105)
ASR World
(1/105)
Cases CIR (1/105) ASR China
(1/105)
AS World
(1 05)
Cases CIR
(1/105)
ASR China
(1/105)
ASR World
(1/105)
Lip, oral cavity, & pharynxa C00-C10, C12-C14 214 1¢91 4¢22 3¢13 3¢04 154 6¢06 4¢49 4¢ 60 2¢37 1¢78 1¢65
Nasopharynx C11 301 2¢68 5¢94 4¢94 4¢65 222 8¢73 7¢39 7¢ 79 3¢13 2¢56 2¢36
Oesophagus C15 855 7¢62 16¢87 11¢16 11¢43 660 25¢96 17¢24 18 0 195 7¢72 5¢07 4¢79
Stomach C16 872 7¢77 17¢20 12¢01 11¢84 626 24¢62 16¢79 17 1 246 9¢74 7¢15 6¢48
Colorectum C18-C21 1441 12¢85 28¢43 20¢23 19¢70 824 32¢41 22¢89 23 3 617 24¢42 17¢54 16¢17
Liver C22 776 6¢92 15¢31 11¢39 11¢06 610 23¢99 18¢06 18 7 166 6¢57 4¢75 4¢48
Gallbladder C23-C24 136 1¢21 2¢68 1¢94 1¢88 67 2¢64 1¢87 1¢ 69 2¢73 2¢00 1¢86
Pancreas C25 149 1¢33 2¢94 2¢05 2¢02 77 3¢03 2¢13 2¢ 72 2¢85 2¢00 1¢83
Larynx C32 104 0¢93 2¢05 1¢43 1¢44 100 3¢93 2¢71 2¢ 4 0¢16 0¢13 0¢11
Lung C33-C34 2133 19¢02 42¢08 28¢53 28¢84 1583 62¢26 41¢46 44 6 550 21¢77 15¢28 14¢54
Other thoracic organs C37-C38 41 0¢37 0¢81 0¢68 0¢62 26 1¢02 0¢85 0¢ 15 0¢59 0¢51 0¢46
Bone C40-C41 40 0¢36 0¢79 0¢66 0¢63 23 0¢90 0¢79 0¢ 17 0¢67 0¢55 0¢46
Melanoma of the skin C43 19 0¢17 0¢37 0¢32 0¢29 7 0¢28 0¢20 0¢ 12 0¢47 0¢44 0¢36
Breast C50 1179 10¢51 23¢26 19¢68 18¢58 10 0¢39 0¢26 0¢ 1169 46¢27 38¢45 36¢03
Cervix C53 429 3¢82 8¢46 7¢23 6¢76 NA NA NA N 429 16¢98 14¢21 13¢24
Uterus C54-C55 256 2¢28 5¢05 4¢02 3¢91 NA NA NA N 256 10¢13 7¢93 7¢65
Ovary C56 138 1¢23 2¢72 2¢21 2¢08 NA NA NA N 138 5¢46 4¢40 4¢07
Prostate C61 169 1¢51 3¢33 2¢07 1¢97 169 6¢65 3¢95 4¢ NA NA NA NA
Testis C62 4 0¢04 0¢08 0¢08 0¢07 4 0¢16 0¢16 0¢ NA NA NA NA
Kidney C64-C66, C68 137 1¢22 2¢70 1¢88 1¢83 92 3¢62 2¢56 2¢ 45 1¢78 1¢19 1¢09
Bladder C67 266 2¢37 5¢25 3¢55 3¢59 226 8¢89 6¢02 6¢ 40 1¢58 1¢04 1¢01
Brain, CNS C70-C72 158 1¢41 3¢12 2¢55 2¢56 101 3¢97 3¢12 3¢ 57 2¢26 1¢99 1¢82
Thyroid C73 334 2¢98 6¢59 5¢96 5¢39 75 2¢95 2¢72 2¢ 259 10¢25 9¢10 8¢26
Lymphoma C81-C85, C88, C90, C96 335 2¢99 6¢61 5¢10 4¢95 206 8¢10 6¢18 6¢ 129 5¢11 4¢02 3¢76
Leukaemia C91-C95 212 1¢89 4¢18 3¢45 3¢60 109 4¢29 3¢51 3¢ 103 4¢08 3¢39 3¢36
All other sites A_O 519 4¢63 10¢24 7¢24 7¢05 286 11¢25 7¢67 8¢ 233 9¢22 6¢78 6¢20
All sites ALL 11,217 100¢00 221¢29 163¢47 159¢78 6257 246¢10 173¢04 17 87 4960 196¢33 152¢24 142¢05
a Nasopharyngeal cancer is excluded. ICD-10=International Classification of Diseases, tenth revision. CIR=crude incidence rate. ASR=age-standardised incidence rate. NA=not plicable.
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Fig. 3. Geographical pattern of oesophageal cancer age-standardised incidence rates (World standard, per 100,000) in Shantou City, Guangdong Province, China, 2018.
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caseidentification,statisticalanalysis,andreporting.Ourstudyhasdem-
onstrated that theMIS-CASS can efficiently reflect local cancer burden,
andthushasgreatpotentialtobeutilizedforcancersurveillanceinChinain
thefuture.
Over the past 10 years, we have carried out a series of population-
level epidemiologic and etiologic studies on oesophageal cancer in
China [20]. We selected Hua County and Shantou City for this study,
because these areas have both previously been recognised as high-
risk regions of oesophageal cancer, but have not been covered by can-
cer registries. In addition, Hua County in northern China is rural-
dominant and Shantou City in southern China consists of both urban
and rural residents. These two areas together thus represent an ideal
sampling of the true current situation in China as regards health
insurance systems.
Our MIS-CASS was based on individual-level hospitalization med-
ical claims records. The first problem we faced was distinguishing
incident cancer cases from the prevalent cases. For this study we set
a washout time window of at least two years prior to the starting
year of formal statistical analysis of cancer incidence, and all cancer
patients who had claims records within this period were classified as
prevalent cases and excluded from analysis. According to ourFig. 4. Age-specific incidence rates of oesophageal cancer by gender in Hua County, Henan P
ASR=age-standardised incidence rate.estimates, two years should be a sufficiently long period of time, as
the overall cancer incidence rates in these two regions of interest
were stable when the washout time window was set starting from 1
year (Supplementary Figure 2). However, we nevertheless recom-
mend that the time window be as long as possible to eliminate the
impact of prevalent cases to as great an extent as possible. In fact, in
this study, we adopted a washout period of up to six years
(20122017) to estimate the latest cancer specific incidence in these
two areas for the year of 2018, which would make the impact of
“prevalent cases” almost negligible.
In addition, cancer surveillance using claims data also has poten-
tial to miss incident cases due to reimbursement delay. We thus
assessed the time length between admission date and reimburse-
ment date for all the cancer patients, and found that the proportion
of cases with a delay of over six months was extremely low (2¢4%)
(Supplementary Figure 3). This indicates that the MIS-CASS “yields
results in real time” with only a six-month delay, which is far shorter
than the delay in the current cancer surveillance system in China
(three years).
We also evaluated the internal and external validity of the MIS-
CASS. From 2014 to 2018, in Hua County and in Shantou City, the age
distribution of the entire insured population across the study yearsrovince and Shantou City, Guangdong Province, China, 20142018.
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extreme robustness of the “denominator” (Supplementary Figure 4).
The year-by-year percentage changes in cancer incidence rates were
mostly within 10%, denoting the stability of cancer incidence statistics
over time (Supplementary Table 3) [5,6]. In terms of external validity,
the profiles of the common cancer types observed in both of these two
regions were nearly consistent with those in China overall [10]. At the
same time, region-specific cancer patterns were also clearly observed,
such as for oesophageal cancer in Hua County and colorectal cancer in
Shantou City (Supplementary Table 4).
In addition to reporting routine cancer specific incidence statis-
tics, there were also some interesting findings from an epidemiologic
perspective based on the MIS-CASS.
First, over the course of many past decades, Hua County and Shantou
City have been “understood” to be “high-risk” regions for oesophageal
cancer. In this study, we demonstrated for the first time that Hua County
is indeed a high-risk region for oesophageal cancer as expected. Despite
the overall downward trend of incidence, the incidence of oesophageal
cancer in Hua County ranked first before the year of 2015, and remained
third from 2016 to 2018 (Supplementary Table 1). Moreover, the inci-
dence was 2¢1 times as high as the average national level according to
the latest estimate for 2018 [28]. However, Shantou City as a whole was
unexpectedly found not to be a high-risk region for oesophageal cancer,
as the incidence rate ranked only as fifth, and the ASR world was very
close to the national level for both men and women [28]. Nevertheless,
further stratification analysis revealed distinct geographical pattern of
oesophageal cancer incidence in Shantou City. Among its seven districts,
Nanao County, which is an island located at the very east of Shantou
City that is encircled by the sea, had the highest incidence of oesopha-
geal cancer, with an ASRWorld 3¢0 times as high as national rates which
is consistent with previous studies [2830], and 6¢1 times as high as
that of Chaonan district which has the lowest oesophageal cancer inci-
dence. These findings would may provide crucial epidemiologic evi-
dence for establishing prevention and control programmes for
oesophageal cancer in local areas.
Second, we also observed oesophageal cancer demonstrates het-
erogeneity in incidence vis-a-vis gender in these two regions. In
Shantou City, the risk of oesophageal cancer in men was notably
higher than that in women (male-to-female ASR World ratio 4¢02),
and the ratio was higher than that at the national level (male-to-
female ASR World ratio 2¢81) [28]. However, in Hua County which is
a high risk area in the famous “Taihang Mountain Region”, the gender
difference was much smaller with a male-to-female ASR World ratio
of 1¢69. This is consistent with previous studies in Hua County and
Linzhou, which is another well-known high-risk area for oesophageal
cancer that is approximately 50 miles from Hua County [20,31]. This
finding suggested that unlike Shantou City and most other regions in
China, common risk factors for oesophageal cancer are shared by
both men and women. That is, non-gender related environmental
exposure and/or genetic susceptibility and so on were likely to have
played a crucial role in the occurrence of oesophageal cancer in the
Taihang Mountain high-risk areas.
Third, we observed a sharp increase in the all-site cancer inci-
dence rate for females in Hua County in 2016, which mainly resulted
from the contribution of population level screening programmes for
breast cancer and cervical cancer (Supplementary Table 1b, 3, Supple-
mentary Figure 7). After further investigation, we found that a series
of countywide female breast and cervical cancer screening pro-
grammes had been initiated by the Hua County Maternal and Child
Health Hospital together with other health institutions in
20152016, and these programmes endured over the remainder of
the study years. This resulted in a 63% and 107% increase in breast
cancer and cervical cancer incidence from 2015 to 2018.
Basic medical insurance systems in China are administered and
operated by the central and local government, so that the MIS-CASS
by its nature has great strengths. First, the MIS-CASS is a realpopulation level cancer surveillance system with >95% coverage on a
national scale, which is distinct from health insurance systems in
some western countries such as Medicare and the Ontario Health
Insurance Plan [32,33]. Second, the original claims data of MIS-CASS
is of high quality [17], as the diagnostic information is entered by
professionals in qualified medical institutions and verified by officials
from medical insurance managing departments. Third, the propor-
tion of cancer cases missed by the MIS-CASS is low, based on our two
previous individual level comparative evaluation studies [1618].
This is presumed to be the result of economic interest and severity of
cancer. Fourth, the MIS-CASS greatly shortens the reporting delay of
cancer incidence from three years to six months due to management
policies and “real-time” claims settlement in health insurance sys-
tems in China [5,34]. Fifth, the high quality and high standardization
level of the original claims data in the MIS-CASS results in low cost
for analysing and reporting cancer incidence in a large population.
This system is therefore obviously less labor intensive and requires
less time resource input than the current cancer registries in China.
However, some limitations of the MIS-CASS should also be noted.
First, non-inpatient claims records for cancer cases where the patient
was never hospitalized would not be included in the MIS-CASS.
Despite the fact that almost all cancer patients in China are diagnosed
and treated in the form of “hospitalization”, we nonetheless propose
addition of outpatient data and even emergency data to reduce possi-
ble underestimation as much as possible. Secondly, cancer-related
information contained in the claims database is relatively limited at
present. Integration of more diagnosis-related information (such as
ICD-O-3 codes including morphology and topography) into the data-
base would further increase the accuracy of this system for ascertain-
ing cancer cases, and expand its applicability.
As indicated in the 13th Five-Year Plan (20162020) in China and
"Healthy China 203000 Planning Outline, great efforts will be made to
promote the integration, sharing, mining, and application of big data
in different health-related areas. In 2017, the National Health and Fam-
ily Planning Commission proposed accelerating the informatization of
surveillance andmanagement of major chronic diseases at the national
level. This study has established the value of MIS-CASS for applying big
data in medical insurance systems to cancer surveillance, demonstrat-
ing that the MIS-CASS can efficiently reflect local cancer burden and
guarantee data security and privacy. We therefore recommend that
the MIS-CASS be adopted on a larger scale, especially in areas with
high quality China cancer registries, so that parallel comparative stud-
ies could be conducted to further validate the completeness and accu-
racy of the MIS-CASS. This will provide new insights into the reform
and development of cancer surveillance strategy in China.
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